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The activation of T  lymphocytes for antigen-induced  proliferative responses 
(1), T  lymphocyte cytotoxicity (2), delayed-type hypersensitivity (3), and helper 
function  for antibody responses  (4)  requires  their  recognition  of the  nominal 
antigen  on  the  surface  of an  antigen-presenting  cell  (APC) 1 bearing  Ia-DR 
molecules  encoded  by the  I  region  of the  major  histocompatibility  locus.  In 
addition to the requirement for "joint recognition,"  the APC provides a  second 
signal for T  lymphocyte activation, the cytokine interleukin  1 (IL-1) (5). 
Monocytes and other cell types, including dendritic cells, all have been reported 
to produce IL-1  and to be effective APC (6-8).  Recently, normal  B cells (9), B 
cell  tumors  expressing  Ia  antigens  (10-12),  and  Epstein-Barr  virus  (EBV)- 
transformed B cell lines (13) all have been reported to exert an effective antigen- 
presenting  function  for T  lymphocyte activation.  Furthermore,  murine  B  cell 
lymphoma  cells  have  been  shown  to  "process"  and  present  antigens  (I0)  in  a 
manner  similar  to that  reported  for murine  (14) as well as human  monocytes 
(15). These B cell lines, however, have not been reported to secrete IL-1 or any 
other soluble factors, raising critical questions concerning the importance of such 
second signals for T  cell activation. 
In this study we report that ROHA-9, a human EBV-transformed lymphoblas- 
toid cell  line  that  is an  effective APC,  constitutively produces a  soluble factor 
with  biochemical  and  biological  characteristics  resembling  those of monocyte- 
derived human  IL-I. The IL-l-like activity was undetectable in crude superna- 
tants, but was evident after gel fractionation studies which, in addition, revealed 
the presence of a  coexistent  inhibitory  factor.  The  biochemical and  biological 
properties of this inhibitory factor have also been investigated. 
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i Abbreviations  used in this  paper."  APC,  antigen-presenting cells; BCGF,  B cell growth factor; Con 
A, concanavalin A; CSF, colony-stimulating factors; EBNA, Epstein-Raft nuclear antigen; EBV, 
Epstein-Barr virus; HSA, human serum albumin; Ig, immunoglobulin; IL-1, interleukin 1; IL-2, 
interleukin 2;  mAb; monoclonal antibodies; MLR, mixed leukocyte reaction; PBS, phosphate- 
buffered saline; PEG, polyethylene  glycol; PMA,  phorbol myristic  acetate; SLO, Streptolysin O; SpA, 
S. aureus protein A. 
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Materials and Methods 
Animals.  C3H/HeJ mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME). 6-8-wk old female mice were used. Animals were fed and supplied with water ad 
libitum. 
Reagents.  Streptolysin O (SLO) and iipopolysaccharide Escherichia coli 055:B55 (LPS) 
were purchased from Difco Laboratories (Detroit, MI). Staphylococcus aureus protein A 
(SPA) and concanavalin A (Con A) were purchased from Pharmacia (Uppsala, Sweden). 
3HTdR (1.9  mCi/mM)  was  obtained  from Amersham  (Amersham,  UK).  RPMI  1640 
tissue culture medium was purchased from Gibco laboratories (Grand Island,  NY) and 
supplemented with  100 U/ml penicillin,  100/~g]ml streptomycin (Microbiological Asso- 
ciates, Walkersville, M D), and 2 mM glutamine (Gibco Laboratories). Fetal calf serum was 
purchased  from  Hyclone (Logan,  VT)  and  2-mercaptoethanol  from  Eastman  Kodak 
(Rochester, NY). Hepes buffer was obtained from Gibco Laboratories. 
Production  and Biochemical  Characterization  of Soluble  Factors.  Human IL-1 was pro- 
duced as previously described (15) by stimulating adherent monocytes with 25 ~g/ml LPS 
for 48  h  in  RPMI  1640  medium supplemented with  1 mg/ml  human  serum albumin 
(HSA) (generously provided by the American Red Cross, Bethesda, MD), 2 rnM glutamine, 
100 U penicillin, and 100 t~g/ml streptomycin. Supernatants were harvested and the IL- 
l  was  partially  purified  by  sequential  (NH4)2SO4 purification,  DEAE-Sephacel  anion 
exchange chromatography, and  Sephacryi S-200  gel  filtration as  previously described 
(15). 
Supernatants from ROHA-9 cell cultures were collected at the times indicated in the 
figure legends and processed as follows:  for ammonium sulfate precipitation 47.6 g of 
(NH4)~SO4 were added to 100 ml of supernatant under gentle stirring to achieve a final 
concentration of 75%. The precipitated proteins were collected by centrifugation at 5,000 
g for 10 min and dialyzed extensively against 20 mM NaCl buffer, pH 7.8 containing 20 
mM Tris 0.01% polyethylene glycol (PEG) (6,000 tool wt) and 50 t~g/ml of gentamicin 
(Gibco Laboratories). For DEAE-Sephacel chromatography the samples were centrifuged 
(15,000 g for 10 min) to remove denatured proteins and applied to the anion exchange 
column at 3 mg of protein per ml of gel. The samples were eluted with a linear NaCI 
gradient  (20  mM  to  400  raM),  3-ml  fractions were  collected, dialyzed extensively in 
phosphate-buffered saline  (PBS)  containing 0.01%  PEG and antibiotics, and tested as 
described below. 
For gel filtration, (NH4)SO4-precipitated supernatants were dialyzed extensively against 
PBS containing 0.01% PEG and antibiotics. 2-ml samples were applied to a Sephacryl-S- 
200 superfine (Pharmacia) column (2.5 × 90 cm) that had been previously calibrated with 
the following markers: aldolase (158,000 mol wt), bovine serum albumin (67,000 mol wt), 
ovalbumin (45,000 tool wt), soybean trypsin inhibitor (21,500 tool wt), and cytochrome c 
(12,354 mol wt). Aliquots of 3 ml were collected by elution with PBS supplemented with 
0.01% PEG and 50 t~g/ml gentamicin at a flow rate of 20 ml/h and then tested as described 
below. The fractions active in the IL-1 assay or in the assay  for inhibitory activity (see 
below) were pooled, concentrated by Amicon ultrafiltration with PM 10 Diaflo membrane 
(Amicon Corp.; Danvers, MA), and dialyzed extensively against 0.01% PEG. The samples 
were loaded onto a preparative isoelectric focusing column (LKB) in a 100-ml 5% to 50% 
sucrose gradient with  0.01%  PEG and  2% ampholites, pH  3.5  to  10 (LKB). The pH 
gradient was formed over a period of 18 h at 1,600 V. 3-ml fractions were collected and 
the pH  was determined. Fractions were dialyzed extensively against  PBS (with 0.01% 
PEG, 50/~g/ml gentamicin), filtered, and tested as described below. 
Cell Preparation.  The human EBV-transformed B lymphoblastoid cell line ROHA-9 
was established and cloned by Hall and Muchmore, as described in detail elsewhere (Hall 
and Muchmore, submitted for publication). ROHA-9 cells were cultured in RPMI  1640 
supplemented with 10% heat-inactivated FCS at 0.2 ×  106/ml and grown up to 1.2 ×  106 
in 6 d. These cells were tested for nonspecific esterase, peroxidase, surface immunoglob- 
ulin (Ig), Ig production, and Epstein-Barr Nuclear Antigen (EBNA) positivity by standard 
techniques. The reactivity of ROHA-9  cells  with  monoclonal antibodies (mAb) AF10- SCALA  El"  AL.  1639 
(aHLA-DR) (16), aLeu-M1  (17), aLeu M3 (18), aOKM1  (19), and a-Leu  10 (20) was 
studied by flow cytometry (Ortho Cytofluorograph). 
Highly purified T  cells were prepared by depletion of adherent  cells from PBL by 
plastic adherence and passage  over nylon  wool column followed  by fractionation on a 
seven-step discontinuous Percoll (Pharmacia)  density gradient ranging from 40% to 57% 
Percoli with each step varying from the next by 2.5% concentration (21). Lymphocytes 
recovered from high density fraction 6 were consistently free of contaminating monocytes 
(<0.1% by nonspecific  esterase)  and were utilized  as responder cells in cocultures with 
ROHA-9 cells (see below). 
Culture Conditions.  For Con A, SpA, and mixed leukocyte reaction (MLR) response, 
purified  T  lymphocytes were cultured  in  RPMI  1640 supplemented  with  10%  heat- 
inactivated  pooled human AB serum,  2 mM glutamine,  10 mM Hepes, and  50 #g/ml 
gentamicin  at  2  x  105  cell/well  in  0.2-ml  cultures  in  the  presence  of the  indicated 
concentrations of ~aTC-irradiated (5,000 rads)  ROHA 9 cells for 3 d  (Con A and SpA 
response) or 7 d (MLR). Cultures were pulsed for the last 16 h with 1 #Ci [SH]thymidine 
and harvested using an automated harvesting  system. To obtain an SLO response, 5 x 
105 unfractionated PBL were cultured in the same medium in the presence of optimal 
concentrations of SLO (1.20 final dilution) and linear dilutions of the inhibitory factor as 
specified  in  figure legends.  IL-1  and  IL-2 assays were performed exactly  as described 
previously (15) by using a single cell suspension  of C3H/HeJ thymocytes or the IL-2- 
dependent CT6 cell line (22), respectively. 
Results 
Surface Marker and Functional Characteristics  of ROHA-9 Cells.  ROHA-9 cells 
were  100%  EBNA positive, <1%  nonspecific esterase and peroxidase positive, 
92% surface IgM positive, produced 20 ng/ml of IgM into the medium, reacted 
strongly (98%) with AF-10, a  mAb that  recognizes a  common determinant  on 
both monocytes and B cell DR molecules, and with aLeu-10 mAb (94%), which 
is specific for B cells. In contrast, ROHA-9 cells did not react with aLeu-M 1 or 
aOKM 1 mAb, both markers of the myelomonocytic lineage. 
Functionally, ROHA-9 cells were potent stimulators in the one-way allogeneic 
MLR. In fact, as shown in Fig. 1, irradiated ROHA-9 cells stimulated a significant 
proliferative  response  by allogeneic  purified  T  lymphocytes at  a  stimulator/ 
responder ratio as low as 1:40. We then tested the capacity of ROHA-9 cells to 
fulfill an effective accessory function for T  lymphocyte responses to Con A  or 
SpA (15,  26).  ROHA-9 cells were effective APC for proliferative  response  of 
purified T  lymphocytes to both Con A or SpA (Fig.  1). 
Biochemical  Characterization  of  ROHA-9-derived  Interleukin  1.  We  tested 
whether  ROHA-9  cells,  which  had  the  capacity  to  present  alloantigens  and 
polyclonal  stimulants  to  T  lymphocytes,  might  secrete  an  IL-l-like  soluble 
factor(s).  Supernatants  from  6-d cultures  of unstimulated  ROHA-9 cells were 
concentrated  (10×)  by  Amicon  membrane  system,  dialyzed,  and  tested  for 
interleukin  1  activity.  These  crude  supernatants  showed  no  detectable  IL-1 
activity but rather had some inhibitory effects on the response of mouse thymo- 
cytes to suboptimal doses of Con A (data not shown). Therefore, we performed 
gel  fractionation  studies  of the  supernatants  in  the  attempt  to  separate  the 
inhibitory activity from the putative presence of IL-1 activity. 
Aliquots of 10-fold concentrated supernatants were applied to Sephacryl $200 
columns and the eluted 3-ml fractions were tested for both IL-l-like activity and 
inhibition of mouse thymocyte response to a standard preparation  of IL-1. The 1640  A  HUMAN  EBV-B  CELL  LINE  SECRETES  INTERLEUKIN  1 
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FIGURE  1.  Accessory cell function of ROHA-9 cells for T  lymphocyte activation. 2.5 x  105 
monocyte-depleted T  lymphocytes were cultured with the indicated percentages of irradiated 
(5,000 rad) ROHA-9 cells for 3 d in the case of Con A or SpA responses, or for 7 d  for one- 
way MLR. Data are expressed as mean cpm of triplicate cultures. The standard deviations of 
the experiments shown in this as well as in the next figures were <5-10% (not shown). Results 
are representative of several experiments. A, MLR; O, Con A (3 #g]ml); rl, SpA (10 #g/ml). 
results (Fig.  2B)  showed that a  major peak of IL-l-like activity eluted in  the 
range of 15-18,000  tool wt, with a second peak of activity in the range of 32- 
35,000. The active fractions of these two peaks of IL-l-like activity were pooled, 
concentrated to 2 ml, dialyzed, and reapplied to the same $200 gel column. The 
eluted samples showed a  similar pattern  of activity, suggesting that  the  32K 
ROHA-9-derived IL-1 activity was due either to molecular weight heterogeneity 
or  to  molecular complexes  of  15K  IL-1  with  each  other  or  with  unrelated 
peptides (data not shown). 
The inhibitory activity eluted in a single peak, in the range of 95-100 K tool 
wt (Fig. 2 C). 
To study whether ROHA-9-derived IL-l-like activity, like monocyte-derived 
IL-I  (15, 25), also binds to anion exchange resins,  10× concentrated ROHA-9 
supernatants were applied to a  DEAE-Sephacel column. The IL-l-like activity 
eluted from DEAE-Sephacel with 50-80 mM NaCI salt concentration and with 
a second peak eluting with 110-130 mM NaCI (Fig. 3 A). The second peak may 
consist of a complex of IL- 1 and BSA as observed for monocyte-derived human 
IL-1 (15) (Fig. 3A). 
The  inhibitory  activity in  10x  concentrated supernatants  was  eluted from 
DEAE-Sephacet in a single peak of activity with  150 mM NaC1 (Fig. 3B). Next, 
the major (15-18K tool wt) IL-1 active peak from $200 gel filtration was applied 
to  a  preparative  isoelectrofocusing column  in  a  100-ml,  5%  to  50%  sucrose 
gradient with 2% ampholites, pH 3.5 to  10.  The results (Fig. 4A) showed that 
ROHA-9 IL-1 exhibited IEF heterogeneity similar to that reported for monocyte- 
derived human IL-1 (26), with a major peak of activity at pI 7.3 and two others 
at pI 6.1  and 4.1. The 32-35K second peak of activity showed a similar profile 
on IEF (data not shown). SCALA  ET  AL.  1641 
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FIGURE 2.  Gel fractionation profiles of ROHA-9 cell culture supernatants. (NH4)2SO4  pre- 
cipitated supernatants were dialyzed and applied to Sephacryl $200 superfine packed column. 
Each fraction was dialyzed extensively and tested at  1:8 final concentration. Panel A shows a 
typical separation pattern of IL-1  generated by LPS stimulated human monocytes (X).  Panel 
B shows the ROHA-9 derived IL-1  activity (O). Panel C shows the inhibitory activity for IL-1 
(O).  OD  280  nm (A). Data are expressed as cpm or as percentage of inhibition of triplicate 
cultures. 
The fractions, from the $200 gel column, that inhibited the C3H/HeJ mouse 
thymocyte response to IL-1  were pooled and also applied to a IEF column. The 
inhibitory activity was recovered from such a preparative IEF column in a single 
peak at pI 4.75 (see Fig. 4B). 
Capacity of ROHA-9-derived IL-I to Enhance the Proliferative  Response ofT Lym- 
phocytes  to  Con  A.  ROHA-9-derived  IL-1  partially  purified  by  sequential 
(NH4)2804  precipitation, DEAE-Sephacel chromatography, and $200 gel filtra- 
tion,  like  monocyte-derived  IL-1  (24),  enhanced the  proliferative  response  of 
monocyte-depleted human T  lymphocytes to suboptimal doses (1 pg/ml) of Con 
a  (Fig. 5). 
Kinetics  of Production  of lL-1  and of Inhibitory Factor by ROHA-9  Cells.  The 
production of IL-l-like activity and of the inhibitory factor was followed daily 
for the 6-d period of exponential growth of the ROHA-9 cell line. As shown in 
Fig. 6, the secretion of IL-l-like activity peaked at day 3 and was stable through 
day 6. 
Murine  as  well  as  human  monocytic  cell  lines  can  be  induced by  phorbol 1642  A  HUMAN  EBV-B  CELL  LINE  SECRETES  INTERLEUKIN  1 
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FIGURE  3.  DEAE-SephacelchromatographyofROHA-gcellculturesupernatant.(NH4)2SO4 
precipitated supernatants were dialyzed, applied to DEAE-Sephacel column, and eluted with 
a  20-400  mM NaCI gradient (El). The  ROHA-9 cell--derived IL-! activity eluted at 50-80 
m M NaCI salt concentration (e) and with a  second minor peak of activity at  110-120  NaCI 
(panel A). The inhibitory factor (a) eluted as a single peak of activity at 150 with NaC1 (panel 
B) (A). OD (280 mm) of the eluted fractions. 
myristic acetate (PMA) to secrete greater levels of IL-1 activity (24, 25). There- 
fore, we tested whether ROHA-9  cells also could also be induced to produce 
greater levels of IL-1  activity by PMA. As shown in  Fig.  6,  unstimulated and 
PMA-stimulated (20 ng/ml) ROHA-9 cells produced comparable levels of IL-1 
activity. No increase in  IL-1  production was obtained by stimulating ROHA-9 
cells with 50-1,000 ng/ml of PMA (data not shown). 
An inhibitory factor was detectable in supernatant of unstimulated cultures of 
ROHA-9  cells  starting  at  day  2  and  was  present  during  the  entire  6  d  of SCALA  ET  AL.  1643 
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FIGURE~ 4.  Isoelectrofoucsing  of ROHA-9  cell supernatants.  The  15-18K  tool  wt fractions 
of IL-1  activity  from  $200  gel filtration,  which  were active  in  IL-1  assay or the  95-100,000 
tool wt inhibitory fractions were applied to a preparative  isoelectrofocusing  column  with a pH 
gradient  (O) from  3.5  to  10.  Panel A  shows  ROHA-9  cell-derived  IL-1  activity  (O).  Panel  B 
shows the inhibitory activity (0). All fractions were tested at  1:8 final concentration. 
logarithmic  growth.  However,  when  cultures  were  stimulated  with  20  ng/ml 
PMA,  the inhibitory activity  peaked at day 2, but decreased  by day 3  and was 
nearly  undetectable  by  day  4  to  6.  It  is  of interest  that  10-100  ttg/ml  LPS 
similarly  did  not  increase  the  production  of  IL-1  activity,  but  decreased  the 
production  of the  inhibitory  factor  (data  not  shown).  Taken  collectively,  the 
above  data suggest  that "activation"  of ROHA-9  cells by PMA or by LPS may 
lead  to  a  selective  block  of  the  secretion  of  the  inhibitory  factor,  while  the 
production of IL-I activity remains unaffected. 
Biological  Characteristics  of the  Inhibitory  Factor Produced  by  the ROHA-9  Cell 
Line.  Since  IL-1  has  been  reported  to  be  a  necessary  second  signal  for  T 
lymphocyte  proliferative  responses  (15),  we  tested  whether  the  95K  factor 1644  A  HUMAN  EBV-B  CELL  LINE  SECRETES  INTERLEUKIN  1 
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A in the absence of monocytes. 2.5 x  105 monocyte-depleted T  lymphocytes from fraction 6 
of discontinuous Percol] density gradient were cultured in presence of 1 #g/ml Con A and the 
indicated concentrations of partially purified IL-1. Data are mean cpm from triplicate cultures. 
Results are representative of five experiments. 
60- 
o IL-I  PI~A- 
~'-" 50-  ~  • ,L-~  P.~a/~o 
x  40- 
0 Jnh.Pt4A- 
Q)  30- 
£ 
100 
0  0  0 
O-  ~  ,  ,  ,  "--------  ~  -------  .7  Lo 
1  2  3  4  5  6 
days of culfure 
FIGURE 6.  Kinetics of production  of the IL-l-like activity and of the inhibitory factor by 
ROHA-9 ceils.  Supernatants from unstimulated or PMA-stimulated (20 ng/ml) ROHA-9 cell 
cultures were harvested at the indicated days of the logarithmic growth. (NH4)zSO4-precipi- 
rated proteins were applied to single DEAE-Sephacel anion exchange columns and eluted by 
20-400  mM  linear  NaCI salt  gradient.  2-ml  fractions  were collected, dialyzed extensively 
against PBS (with 0.01%  PEG and antibiotics), and tested for IL-l-like activity in the C3H/ 
HeJ thymocyte costimulator assay  and for the capacity to inhibit the response of C3H/HeJ 
mouse  thymocytes  to  a  standard  preparation  of IL-I.  Fractions  were  tested  at  1:8  final 
concentration.  Results are  mean  of triplicate  cultures.  Results are  representative  of three 
experiments. SCALA  ET  AL.  1645 
produced  by ROHA-9  cells was inhibitory for T  lymphocyte  response  to poly- 
clonal stimulants such as Con A,  for soluble antigens such as SLO, and for the 
T  lymphocyte response to alloantigens. We observed a dose-dependent inhibition 
of T  lymphocyte  responses  to  suboptimal  doses  of Con  A  (1  #g/ml),  but  no 
inhibition when optimal doses (10 #g/ml) of Con A  were used (Fig. 7 A). 
We also observed a dose-dependent inhibition of the response of T  lymphocytes 
to SLO  or alloantigens  by the partially  purified preparation  of 95K  inhibitory 
factor (Fig. 7B). 
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FIGtmE  7.  Effects of ROHA-9 cell-derived  inhibitor factor  on  T  lymphocyte response  to 
stimulants. Panel A: 2.5  x  10 5 unfractionated  PBL were cultured for 3 d  in the presence of 
optimal (10 #g]ml, zX) or suboptimal (1  #g/ml, X) doses of Con A  and various concentration 
of ROHA-9 cell-derived  inhibitory factor partially purified by (NH4)2SO4  precipitation  and 
Sephacryl $200  gel  filtration.  A,  Con A  10  ~g/ml;  x,  Con A  1 #g/ml.  Panel B:  2.5  x  105 
unfractionated PBL were cultured for 6 d in the presence of optimal doses of SLO (1.20 final 
concentration)  (16).  For  MLR  studies  (panel  B),  2.5  ×  10 s  purified  T  lymphocytes  were 
cultured for 7 d with irradiated (3,000  rad) allogeneic monocytes and various concentrations 
of inhibitory factor.  Cultures were pulsed for the last  16 h  with  1 #Ci SH-TdR.  Results are 
representative of five experiments. O, MLR; II, SLO response. 1646  A  HUMAN  EBV-B  CELL  LINE  SECRETES  INTERLEUKIN  1 
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FIGURE 8.  Effects  of ROHA-9 cell-derived inhibitor on IL-1 and IL-2 responses. 1 x  10  ~ 
C3H/HeJ mouse thymocytes were cultured for 3 d with suboptimal doses (1 #g/ml) of Con A 
and a standard preparation of IL-1 CO) or IL-2 (O) in the presence of various concentrations 
of a preparation of the inhibitor partially purified by (NH4)2SO4 precipitation and $200 gel 
filtration. For 1L-2 inhibition, 1 x  104 IL-2-dependent CT6 cells were cultured for 48 h in 
the presence of a standard preparation of IL-2 and the indicated concentration of  the inhibitor 
factor (Q). Cultures were pulsed and harvested as described above. Results are mean -4-- SEM 
of triplicate cultures and are representative of several experiments. 
The activation of T  lymphocytes is the result of a  complex cascade of events 
(27) in which at least two soluble factors, IL-1 and IL-2, sequentially interact so 
that  inhibition  of either  one  or  both  of them  could  result  in  decreases  in  T 
lymphocyte proliferation. We therefore tested the capacity of a partially purified 
preparation  of inhibitory  factor  to  inhibit  the  response  of C3H/HeJ  mouse 
thymocytes to a  standard preparation of monocyte-derived human IL-1, and to 
inhibit the effect of a  standard preparation of IL-2 on the growth of the IL-2- 
dependent  CT6  cell  line.  As  shown  in  Fig.  8,  we  observed a  dose-dependent 
inhibition  of the  95K inhibitory factor on mouse thymocyte response  to IL-1, 
while  the  factor had  no effect on the  response  of CT6  cells.  In  addition,  the 
inhibitory factor did  not  inhibit  the  comitogenic response  of thymocytes to a 
standard  preparation  of IL-2  (Fig.  8).  These  data  suggest  that  the  inhibitory 
effect of the  O5K factor from ROHA-9  cultures is exerted by interfering with 
the  helper  effects of IL-1.  On  this  basis  the  inhibitory  factor will  be  named 
hereafter "contra-IL- 1 ." 
To  better  understand  the  mechanisms  of  this  inhibition,  we  investigated 
whether the target cells of contra-IL-1  bear detectable receptors for this inhib- 
itor. C3H/HeJ mouse thymocytes were incubated (37 °C, 5% CO2 with frequent 
gentle agitation) at 3  x  107/ml with aliquots of the eluted O5K inhibitor factor 
or with equivalent 90-100K mol wt $200 fractions of FCS-containing medium. 
After 1 h, cells and supernatants were tested for their capacity to respond to IL- 
l  or to inhibit the response of untreated thymocytes to the same standard amount 
of IL-1, respectively. As reported in Fig. O, the inhibitory effects of the standard 
preparation of 95K contra-IL-1 were completely absorbed by thymocytes at the SCALA  ET  AL.  1647 
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FIGURE 9.  Selective absorption of ROHA-9 cell-derived inhibitor. C3H/HeJ  mouse thy- 
mocytes or CT6 cells were incubated (37°C, 5% CO~) with various dilutions of a  partially 
purified preparation of inhibitor at 2 ×  107/ml. 2 h later, cells and supernatants were collected 
by centrifugation. Thymocytes were then cultured for 3 d in presence of suboptimal doses of 
Con A (1 ug/ml), a standard preparation of IL-1 and various dilution of unabsorbed prepara- 
tions of inhibitor (I), The preparation of inhibitor was tested after thymocyte absorption ([]) 
or after CT6 absorption (O). Thymocytes, which were pulsed with the indicated linear dilution 
of inhibitor for 2 h, were washed three times with PBS and tested for proliferative response 
to a standard preparation of IL-1 in presence of suboptimal doses of Con A (1 ug/ml) (0). In 
experiments done  in parallel, thymocytes were  incubated with an equivalent 90-100,000 
dalton mol wt range preparations from $200 gel columns loaded with FCS-containing  medium 
and showed a normal thymocyte response to the standard preparation of IL-1 (data not shown). 
Results are representative of four experiments. 
dilutions tested. Thymocytes that had absorbed the factor were in turn inhibited 
from responding to a  standard  preparation  of monocyte-derived IL-1.  In con- 
trast, CT6 cells failed to absorb significant levels of the inhibitory activity. The 
data  suggest  that  the  ROHA-9-derived  inhibitory  factor  can  be  specifically 
absorbed by thymocytes that also are the target of the biological effects of IL-1. 
Discussion 
Previous studies by Chestnut and Grey have shown that normal murine B cells 
(9) as well as Ia-antigen-bearing  mouse B cell tumor lines (10-12) could serve as 
effective APC for antigen-driven T  cell activation. Moreover, EBV-transformed 
human B cells have been reported to present the soluble antigen tetanus toxoid 
to Ia-DR compatible T  lymphocytes (13).  In line with these findings we report 
in the present study that a human EBV-transformed B cell line, ROHA-9, which 
exhibited many of the phenotypic markers of normal  B cells, was an effective 
APC for T  lymphocyte responses to the polyclonal stimulants Con A or SpA and 
for alloantigens in MLR. 
The  accessory cell function  of APC  has been associated with  secretion of a 
soluble factor identified as the 12-18K tool wt IL-1 (5,  15). The data presented 
in this study also show that a  human  EBV-transformed  B lymphoblast line can 
constitutively  secrete  a  soluble factor  that  showed biochemical  and  biological 1648  A HUMAN EBV-B CELL LINE SECRETES INTERLEUKIN 1 
characteristics similar to  those reported for the monocyte-derived human IL-1 
(26). The anion exchange chromatography and IEF profiles of ROHA-9-derived 
IL-1  were also consistent with that reported for the monocyte-derived human 
IL-1  (15, 26). Moreover, the major peak of the ROHA-9-derived IL-1 activity 
eluted in the range of 15K mol wt, compatible with the known characteristics of 
human IL-1.  However, we observed a  second peak of activity in the range of 
32K. While we cannot rule out that this second peak of activity might be due to 
molecular aggregation of the 15K mol wt IL-1 activity, it is possible that the 32K 
peak might be a  biochemical variant of human IL-1  secreted by the ROHA-9 
lymphoblastoid  cell  line.  A  similar  molecular weight  heterogeneity has  been 
reported  for  cutaneous  T  cell  lymphoma-derived TCGF  (IL-2)  (28)  and  for 
human interferon that is constitutively produced by virus-infected human lym- 
phoblastoid cell lines (29).  The nature and significance of the molecular weight 
heterogeneity of IL-1  remain  unknown  since no  functional differences were 
found between these two peaks of activity (data not shown). 
In further studies, we have been able to demonstrate that six of seven other 
EBV-transformed human B cell lines that produced factors with biological and 
biochemical characteristics of IL-1  can be  effective APC.  Moreover, another 
EBV-B cell line constitutively secreted an IL-1  activity as well as an inhibitory 
factor (Kuang et al., submitted for publication). Furthermore, preliminary results 
(G.  Scala,  work  in  progress) also  indicate that  when appropriately stimulated 
highly purified human normal B cells may secrete a soluble factor with some of 
the characteristics of IL-1. 
In  addition  to  the  above-mentioned  role  in  antigen  presentation,  IL-1  is 
involved in  the generation of cytotoxic effector cells (30),  acts  synergistically 
with IL-2 and ~,-IFN in boosting natural killer activity (31), stimulates fibroblast 
proliferation (26) and collagenase production (32), and induces fever (33) and 
the production of acute phase proteins (34). Although the B cell line IL-l-like 
factor needs to  be  tested for these other effects, it  is  likely that  B  cells may 
actively participate in the same mechanisms of immunity and inflammation in 
which IL-1  is also involved.  Furthermore, IL-1  has been recently reported to 
enhance B cell activation synergistically with T  cell-derived factor such as B cell 
growth factor (BCGF) (35), thus suggesting that B cell-derived IL-1  may exert 
a positive self-regulatory effect on B cell activation. 
The other new observation was that ROHA-9 cells constitutively produced an 
inhibitory factor. This inhibitory factor appeared to inhibit the CSH/HeJ mouse 
thymocyte response to a  standard preparation of IL-1, but did not inhibit the 
response of either mouse thymocytes or of CT6 cells to a standard preparation 
of IL-2.  Furthermore, the inhibitory factor was selectively absorbed by mouse 
thymocytes but  not by CT6  cells, suggesting a  selective interference with the 
mechanism of thymocyte activation  by  IL-1.  As  expected,  partially  purified 
preparations  of contra  IL-1  also  inhibited  in  a  dose-dependent  manner  the 
response  of PBL  to  the  soluble  antigen  SLO  or  the  response  of purified  T 
lymphocytes to alioantigens in a one-way allogeneic MLR. Furthermore, contra- 
IL-1 inhibited the response of PBL to suboptimal (1 #g/ml) but not optimal (10 
#g/ml) doses of Con A, raising the question of whether, as suggested by recent 
observations (36),  the activation of T  lymphocytes by large amounts of Con A SCALA ET AL.  1649 
might  circumvent the  requirement for  IL-I,  or  whether the  factor  was  not 
sufficiently potent to overcome the amount of factor(s) (namely IL-1) produced 
during activation of PBL with optimal doses of Con A. 
It was of interest that in ROHA-9 cultures stimulated with PMA or LPS the 
production of the inhibitor decreased by day 3,  becoming then undetectable. 
The data suggested that stimulation of ROHA-9 cells might lead to a  selective 
suppression of the synthesis of the inhibitory factor, and consequently a relative 
increase in IL-l-like activity. These results may explain the paradoxical obser- 
vation that these cells can act as APC even though they constitutively produce 
an inhibitory factor. 
It is of note that, while positive regulation of IL-1  production by monocytes 
through secretion of CSF (37) or y-IFN by T  cells (38) is established, little data 
have been reported on negative regulation of IL-1  secretion and/or action by 
soluble factors. Recently, an inhibitory factor, which specifically inhibited IL-1 
activity, has been identified in urine from patients with fever (39). The cellular 
source of such inhibitory factors, however, was unknown. The data presented in 
this paper suggest that the IL-l-secreting cells may also negatively regulate the 
action of IL-I through secretion of inhibitory factor(s) such as contra IL-I. 
Summary 
In the present paper we report that the ROHA-9  cell line, an Epstein-Barr 
virus  (EBV)-transformed  human  B  cell  line  with  accessory  cell  capabilities, 
constitutively secretes a soluble factor with the biochemical and biological char- 
acteristics of human monocyte-derived IL-1. The IL-1  derived from ROHA-9 
augmented murine thymocyte proliferation and enhanced the proliferative re- 
sponse of human T  lymphocytes to concanavalin A  (Con  A).  The  ROHA-9- 
derived IL-1 activity eluted from Sephacryl S-200 in two peaks, at 15-18K and 
32-35K mol wt, eluted from DEAE-Sephacei at 50-80 and 110-130 mM NaC1, 
and showed charge heterogeneity with peaks at pI 7.3, 6.1, and 4.1  on isoelec- 
trofocusing (IEF). These findings suggest that B cells may elaborate an IL-l-like 
activity. During the logarithmic growth of ROHA-9 cells, a inhibitory factor that 
inhibited the response of mouse thymocytes to  IL-1  was also produced. This 
factor had a  mol wt of 95K  on  Sephacryl S-200,  eluted at  150  mM  NaC1  on 
DEAE-Sephacel and showed a peak of pI 4.7 on preparative IEF. The inhibitory 
factor appeared to be selective in its effects on IL-1  responses, since it did not 
inhibit the activity of IL-2 on mouse thymocytes or on the growth of the IL-2- 
dependent CT6  cell line. This "contra-IL-l" inhibited the response of murine 
thymocytes to suboptimal (1 #g/ml) but not optimal (10 ug/ml) doses of Con A 
and the response of human peripheral blood lymphocytes to streptolysin O (SLO) 
or to alloantigens. Moreover, the factor could be absorbed by mouse thymocytes 
but not by CT6 cells, and such thymocytes pretreated with contra-IL-1 failed to 
respond to IL-1. Although this inhibitor is the product of a transformed B cell 
line, it may be representative of regulatory substances that normally control IL- 
l  activities either at the extracellular or intracellular level. 
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